TEMT Administration for Alzheimer's Disease

N/A

Waitlist Available

Led By Amanda Smith, MD

Research Sponsored by NeuroEM Therapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up changes from baseline mmse score at two and four months into treatment

Awards & highlights

No Placebo-Only Group

Summary

This trial extends a previous study to see if using TEMT for a longer time can further improve or stabilize cognitive functions in Alzheimer's patients. TEMT uses electromagnetic waves on the head, which may help clear harmful brain proteins and improve memory and thinking skills. This treatment has shown promise in reversing cognitive impairment in Alzheimer's patients in previous studies.

Eligible Conditions

Alzheimer's Disease

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ change from baseline adas-cog at two and four months into treatment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~change from baseline adas-cog at two and four months into treatment

This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline adas-cog at two and four months into treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

ADAS-cog score

Secondary study objectives

Adverse Event Assessment

Clock draw score

Digit span score

+5 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: TEMT AdministrationExperimental Treatment1 Intervention

Subjects in this arm will received Transcranial Electromagnetic Treatment (TEMT) once daily for a 4-month treatment period utilizing the MemorEM 1000 head device.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

MemorEM 1000

2017

N/A

~10

Do I qualify?Apply below to find out